196 related articles for article (PubMed ID: 17634547)
1. Effect of tibolone on breast cancer cell proliferation in postmenopausal ER+ patients: results from STEM trial.
Kubista E; Planellas Gomez JV; Dowsett M; Foidart JM; Pohlodek K; Serreyn R; Nechushkin M; Manikhas AG; Semiglazov VF; Hageluken CC; Singer CF
Clin Cancer Res; 2007 Jul; 13(14):4185-90. PubMed ID: 17634547
[TBL] [Abstract][Full Text] [Related]
2. Estrogen and tibolone metabolite levels in blood and breast tissue of postmenopausal women recently diagnosed with early-stage breast cancer and treated with tibolone or placebo for 14 days.
Kloosterboer HJ; Löfgren L; von Schoulz E; von Schoultz B; Verheul HA
Reprod Sci; 2007 Feb; 14(2):151-9. PubMed ID: 17636226
[TBL] [Abstract][Full Text] [Related]
3. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.
Martino S; Cauley JA; Barrett-Connor E; Powles TJ; Mershon J; Disch D; Secrest RJ; Cummings SR;
J Natl Cancer Inst; 2004 Dec; 96(23):1751-61. PubMed ID: 15572757
[TBL] [Abstract][Full Text] [Related]
4. Clinical effects of tibolone in postmenopausal women after 5 years of tamoxifen therapy for breast cancer.
Dimitrakakis C; Keramopoulos D; Vourli G; Gaki V; Bredakis N; Keramopoulos A
Climacteric; 2005 Dec; 8(4):342-51. PubMed ID: 16390769
[TBL] [Abstract][Full Text] [Related]
5. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
6. Antiproliferative effects of idoxifene in a placebo-controlled trial in primary human breast cancer.
Dowsett M; Dixon JM; Horgan K; Salter J; Hills M; Harvey E
Clin Cancer Res; 2000 Jun; 6(6):2260-7. PubMed ID: 10873076
[TBL] [Abstract][Full Text] [Related]
7. Safety of tibolone in the treatment of vasomotor symptoms in breast cancer patients--design and baseline data 'LIBERATE' trial.
Kenemans P; Kubista E; Foidart JM; Yip CH; von Schoultz B; Sismondi P; Vassilopoulou-Sellin R; Beckmann MW; Bundred NJ; Egberts J; van Os S; Planellas J
Breast; 2007 Dec; 16 Suppl 2():S182-9. PubMed ID: 17983942
[TBL] [Abstract][Full Text] [Related]
8. Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind, placebo-controlled, randomized clinical trial in postmenopausal patients.
Dowsett M; Bundred NJ; Decensi A; Sainsbury RC; Lu Y; Hills MJ; Cohen FJ; Veronesi P; O'Brien ME; Scott T; Muchmore DB
Cancer Epidemiol Biomarkers Prev; 2001 Sep; 10(9):961-6. PubMed ID: 11535548
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of oral tibolone 1.25 or 2.5 mg/day vs. placebo in postmenopausal women.
Hudita D; Posea C; Ceausu I; Rusu M
Eur Rev Med Pharmacol Sci; 2003; 7(5):117-25. PubMed ID: 15214586
[TBL] [Abstract][Full Text] [Related]
10. Tibolone for the treatment of moderate to severe vasomotor symptoms and genital atrophy in postmenopausal women: a multicenter, randomized, double-blind, placebo-controlled study.
Swanson SG; Drosman S; Helmond FA; Stathopoulos VM
Menopause; 2006; 13(6):917-25. PubMed ID: 17006377
[TBL] [Abstract][Full Text] [Related]
11. Tibolone therapy in breast cancer survivors: a retrospective study.
Goutzioulis M; Vavilis D; Agorastos T; Konstantinidis T; Pantazis K; Goutzioulis A; Goulis DG; Makedos G; Bontis JN
J Obstet Gynaecol Res; 2007 Feb; 33(1):68-73. PubMed ID: 17212669
[TBL] [Abstract][Full Text] [Related]
12. Dietary flaxseed alters tumor biological markers in postmenopausal breast cancer.
Thompson LU; Chen JM; Li T; Strasser-Weippl K; Goss PE
Clin Cancer Res; 2005 May; 11(10):3828-35. PubMed ID: 15897583
[TBL] [Abstract][Full Text] [Related]
13. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
Baselga J; Semiglazov V; van Dam P; Manikhas A; Bellet M; Mayordomo J; Campone M; Kubista E; Greil R; Bianchi G; Steinseifer J; Molloy B; Tokaji E; Gardner H; Phillips P; Stumm M; Lane HA; Dixon JM; Jonat W; Rugo HS
J Clin Oncol; 2009 Jun; 27(16):2630-7. PubMed ID: 19380449
[TBL] [Abstract][Full Text] [Related]
14. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
Søiland H; Skaland I; Varhaug JE; Kørner H; Janssen EA; Gudlaugsson E; Baak JP; Søreide JA
Acta Oncol; 2009; 48(4):514-21. PubMed ID: 19107621
[TBL] [Abstract][Full Text] [Related]
15. Tibolone in postmenopausal women with systemic lupus erythematosus: a pilot study.
Vieira CS; Pereira FV; de Sá MF; Paulo LJ; Martins WP; Ferriani RA
Maturitas; 2009 Mar; 62(3):311-6. PubMed ID: 19193505
[TBL] [Abstract][Full Text] [Related]
16. Tibolone histology of the endometrium and breast endpoints study: design of the trial and endometrial histology at baseline in postmenopausal women.
Archer DF; Hendrix S; Ferenczy A; Felix J; Gallagher JC; Rymer J; Skouby SO; den Hollander W; Stathopoulos V; Helmond FA;
Fertil Steril; 2007 Oct; 88(4):866-78. PubMed ID: 17548089
[TBL] [Abstract][Full Text] [Related]
17. Effects of tibolone and continuous combined hormone therapy on mammographic breast density and breast histochemical markers in postmenopausal women.
Valdivia I; Campodónico I; Tapia A; Capetillo M; Espinoza A; Lavín P
Fertil Steril; 2004 Mar; 81(3):617-23. PubMed ID: 15037411
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of tibolone as "add-back therapy" in conjunction with a gonadotropin-releasing hormone analogue in the treatment of uterine fibroids.
Morris EP; Rymer J; Robinson J; Fogelman I
Fertil Steril; 2008 Feb; 89(2):421-8. PubMed ID: 17572410
[TBL] [Abstract][Full Text] [Related]
19. Effects of tibolone on the breast of postmenopausal women.
Wang PH; Cheng MH; Chao HT; Chao KC
Taiwan J Obstet Gynecol; 2007 Jun; 46(2):121-6. PubMed ID: 17638619
[TBL] [Abstract][Full Text] [Related]
20. Improved bleeding profile and tolerability of tibolone versus transdermal E2/NETA treatment in postmenopausal women with female sexual dysfunction.
Nijland EA; Nathorst-Böös J; Palacios S; van de Weijer PW; Davis S; Stathopoulos VM; Birkhaeuser MH; von Mauw E; Mulder RJ; Schultz WC;
Climacteric; 2009 Apr; 12(2):114-21. PubMed ID: 19177255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
